Analysts’ Recent Ratings Updates for Ionis Pharmaceuticals (IONS)

Several brokerages have updated their recommendations and price targets on shares of Ionis Pharmaceuticals (NASDAQ: IONS) in the last few weeks:

  • 3/10/2017 – Ionis Pharmaceuticals was downgraded by analysts at Goldman Sachs Group Inc from a “neutral” rating to a “sell” rating. They now have a $25.00 price target on the stock, down previously from $28.00.
  • 3/7/2017 – Ionis Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $63.00 to $59.00. They now have an “outperform” rating on the stock.
  • 3/6/2017 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $64.00 price target on the stock.
  • 2/28/2017 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $64.00 price target on the stock.
  • 2/27/2017 – Ionis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. “
  • 2/14/2017 – Ionis Pharmaceuticals had its “positive” rating reaffirmed by analysts at BMO Capital Markets. They now have a $63.00 price target on the stock.
  • 2/13/2017 – Ionis Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $51.00 price target on the stock. According to Zacks, “Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. “

Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) opened at 40.07 on Tuesday. The company’s 50-day moving average is $45.67 and its 200 day moving average is $40.78. Ionis Pharmaceuticals Inc has a 52 week low of $19.59 and a 52 week high of $57.00. The stock’s market capitalization is $4.96 billion.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Tuesday, February 28th. The company reported $0.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.45. Ionis Pharmaceuticals had a negative net margin of 77.30% and a negative return on equity of 120.60%. The firm earned $160.30 million during the quarter, compared to the consensus estimate of $97.47 million. During the same period last year, the firm posted ($0.59) EPS. The firm’s revenue for the quarter was up 210.7% on a year-over-year basis. On average, equities analysts forecast that Ionis Pharmaceuticals Inc will post ($0.58) EPS for the current fiscal year.

In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 5,000 shares of the firm’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $55.00, for a total transaction of $275,000.00. Following the completion of the transaction, the senior vice president now directly owns 19,788 shares in the company, valued at approximately $1,088,340. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stanley T. Crooke sold 15,382 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $46.29, for a total transaction of $712,032.78. Following the transaction, the chief executive officer now owns 30,576 shares of the company’s stock, valued at $1,415,363.04. The disclosure for this sale can be found here. Insiders have sold a total of 73,598 shares of company stock valued at $3,556,863 over the last 90 days. 1.86% of the stock is currently owned by insiders.

Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.

5 Day Chart for NASDAQ:IONS

Receive News & Ratings for Ionis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.